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Acute brain injury leads to the recruitment and activation of immune cells including 
resident microglia and infiltrating peripheral myeloid cells (MC), which contribute to the 
inflammatory response involved in neuronal damage. We previously reported that TLR2 
stimulation by peptidoglycan (PGN) from Staphylococcus aureus, in vitro and in vivo, 
induced microglial cell activation followed by autophagy induction. In this report, we 
evaluated if phosphatidyl-inositol-3 kinase (PI3K) pharmacological inhibitors LY294200 
and 3-methyladenine (3-MA) can modulate the innate immune response to PGN 
in the central nervous system. We found that injection of PGN into the mouse brain 
parenchyma (caudate putamen) triggered an inflammatory reaction, which involved 
activation of microglial cells, recruitment of infiltrating MC to injection site, production 
of pro-inflammatory mediators, and neuronal injury. In addition, we observed the accu-
mulation of LC3B+ CD45+ cells and colocalization of LC3B and lysosomal-associated 
membrane protein 1 in brain cells. Besides, we found that pharmacological inhibitors of 
PI3K, including the classical autophagy inhibitor 3-MA, reduced the recruitment of MC, 
microglial cell activation, and neurotoxicity induced by brain PGN injection. Collectively, 
our results suggest that PI3K pathways and autophagic response may participate in the 
PGN-induced microglial activation and MC recruitment to the brain. Thus, inhibition of 
these pathways could be therapeutically targeted to control acute brain inflammatory 
conditions.
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inTrODUcTiOn
Regulation of immune response in the brain is in part accomplished by myeloid cells (MC), 
which represent a diverse group of mononuclear phagocytic cells (1–3). The healthy central 
nervous system (CNS) parenchyma contains only one type of MC, the parenchymal microglial 
cell, which are tissue-resident macrophage confined in an immunosuppressive environment 
(4, 5). However, during parenchymal brain injury, microglial cells become activated and mediate 
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the local immune response. These cells are a prominent source 
of pro-inflammatory factors and oxidative stress mediators, 
such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, 
chemokines, nitric oxide (NO), all of which are further neu-
rotoxic (6, 7). In response to tissue damage, infiltrated blood-
borne MC migrate to the affected area and may contribute the 
neuroinflammatory process (8). Nevertheless, the differential 
roles of these MC populations in CNS disorders have only 
recently been acknowledged.
Toll-like receptors (TLRs) are a family of pattern-recognition 
receptors in the innate immune system. Exogenous and endog-
enous TLR ligands activate microglia that trigger inflammatory 
reactions in CNS (9–11). Recent studies using a mouse experi-
mental brain abscess model have revealed a complex role for TLRs 
in the disease pathogenesis (12). Interestingly, TLR2 participates 
in the innate immune response during the acute stage of brain 
abscess formation induced by Staphylococcus aureus and influ-
ences adaptive immune response (13, 14). Moreover, MyD88, a 
central adapter molecule for many TLRs including TLR2, is a key 
component in the brain innate immunity and was involved in 
exaggerated brain tissue destruction (15, 16). Numerous reports 
suggest that TLR2 contributes to the phagocytosis and autophagy 
in professional phagocytes upon bacterial infection (17–19). 
In line with such evidences, we previously demonstrated that 
intracerebral delivery of peptidoglycan (PGN), the major surface 
component of Gram-positive bacteria and a potent TLR2 agonist, 
leads to the autophagy activation in microglial cells in vivo (20). 
In addition, we observed that both, 3-methyladenine (3-MA) and 
LY294002 inhibited autophagy activation in microglial cells and 
reduced NO production.
Autophagy is a conserved process, whereby cells deliver cyto-
plasmic contents to the lysosomes for removal (21). Although this 
mechanism has a main protective function (22), under several 
conditions, deregulated autophagy may contribute to the inflam-
mation and tissue injury (23). Enhanced autophagy has been 
implicated in various neurological conditions including intracer-
ebral hemorrhage, cerebral ischemia, and spinal cord injury (24, 
25). This self-degradation process is emerging as a core regulator 
of CNS inflammation, aging, and neurodegeneration (26). In the 
brain, it has mostly been studied in neurons, where the delivery of 
toxic molecules and organelles to the lysosomes by autophagy is 
crucial for the neuronal health and survival (27, 28). The initiation 
and course of the autophagic flux are regulated by Beclin 1/Class 
III phosphatidyl-inositol-3 kinase (PI3K)-containing complexes 
(29). Nevertheless, PI3K have dual role in autophagy induction 
since, class III PI3K is required for the autophagosome forma-
tion but class I PI3K interact with principal negative regulator of 
autophagy mTOR (30).
PI3Ks regulate several key events in the inflammatory response 
to damage and infection and they were implicated in the regula-
tion of the pro-inflammatory responses induced by TLR activa-
tion (31). However, the role of PI3Ks in the signaling pathways 
downstream of TLRs on MC is not completely clear. Different 
studies suggested that this pathway can play either positive or 
negative roles in the production of pro-inflammatory cytokines 
(32–34). Furthermore, most of the studies were performed in 
the peripheral immune system, and little is known about the 
contribution of the PI3K activity and autophagy in the regulation 
of the neuroinflammatory response elicited by PGN.
We propose that the inhibition of PI3K and autophagy could 
modulate CNS inflammation induced by TLR2 stimulation. 
Therefore, the aim of this study was to evaluate if intracerebral 
administration of PI3K inhibitors could regulate neuroinflam-
matory responses induced by PGN. We observed that this TLR2 
ligand induced MC activation and colocalization of LC3B and 
lysosomal-associated membrane protein 1 (LAMP1) molecules 
in the CNS. In addition, PI3K inhibitors (including 3-MA) 
prevented the recruitment of inflammatory MC to the brain and 
reduced signs of neurodegeneration. Furthermore, here we show 
that PI3K inhibitors differentially regulated the PGN-elicited 
production of pro-inflammatory molecules and chemokine 
receptor expression in brain MC. Our findings suggest that 
induction of neuroinflammation by PGN was TLR2-dependent 
and it may require PI3K activation and autophagy. Inhibition 
of these pathways in the brain may lead to the downregulation 
of both, microglial cell activation and leukocyte recruitment to 
CNS, resulting in neuronal protection.
MaTerials anD MeThODs
reagents and animals
Peptidoglycan from S. aureus and 3-MA were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). LY294002 were purchased 
from Cell Signaling Technology, Inc. (Beverly, MA, USA). In this 
study, 6- to 8-week-old male C57BL/6J, TLR2 KO, or MyD88 
KO mice were used. C57BL/6J mice were purchased from the 
Facultad de Ciencias Veterinarias, Universidad Nacional de La 
Plata, Argentina; C57BL/6 TLR2-knockout and C57BL/6 MyD88 
knockout mice were purchased from The Jackson Laboratory, 
Bar Harbor, ME, USA. Animal care was provided in accordance 
with the procedures outlined in the “Guide for the Care and Use 
of Laboratory Animals” (NIH Publication No. 86-23, 1985). 
The experimental protocols were approved by the Institutional 
Animal Care and Use Committee of Centro de Investigaciones en 
Bioquímica Clínica e Inmunología (CIBICI), Consejo Nacional 
de Investigaciones Científicas y Técnicas (CONICET). Our ani-
mal facility obtained NIH animal welfare assurance (assurance 
number A5802-01, OLAW, NIH, USA).
surgical Procedures
After 1  week of acclimatization to the housing facility, 6- to 
8-week-old male C57BL/6J mice were anesthetized with a 
combination of ketamine/xylazine. The mouse scalp was shaved 
and scrubbed with hydrogen peroxide. Animals were placed in 
a Thomas stereotaxic frame (Philadelphia, PA, USA). A midline 
incision was made, the skin was retracted, and one small bore hole 
was drilled into the skull. The infusion cannula (30 G; 20 mm) 
was stereotaxically lowered into the caudate putamen (CPU) 
using the following coordinates: anterior, +0.8  mm; lateral, 
+1.5 mm; ventral, −3.2.0 mm, according to the atlas of Franklin 
and Paxinos (2008). The infusion cannulae were connected via 
polyethylene tubing (PE 10; Becton Dickinson, Sparks, MD, USA) 
to 10 µl microsyringes (Hamilton, Reno, NV, USA) mounted on a 
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microinfusion pump (Harvard Apparatus, Holliston, MA, USA). 
Each mouse was injected with 5 µg PGN alone or in combination 
with 0.19 nmol LY2942002 or with 6.37 nmol 3-MA at a volume 
0.35 μl/side at a flow rate of 0.35 µl/min. This volume was selected 
according to the size and structure of these nuclei. Immediately 
after the microinjection, the cannulae were retracted, the holes 
were covered with wax, and the skin was sutured with surgical 
thread. At different time after surgery, mice were killed, and 
brains processed for analysis.
Facs analysis
For ex vivo analysis, at different time points, the mice brains were 
rapidly removed and placed on ice in an acrylic brain matrix 
(Stoelting Co., USA). Coronal brain slices of 2.0 mm containing 
the CPU from each hemisphere were dissected. The rest of brain 
tissues (BRAIN) were collected separately of CPU section, then 
all these sections were homogenized with scissors on ice and 
whole brain cells were costained with anti-CD45 (APC-Cγ7) 
anti-CD11b (PerCPe) antibodies, Ly6C (PE-Cγ7), IA/IE (APC), 
CD86 (PE), CX3CR1 (FITC), and CXCR4 (APC) (Becton 
Dickinson, San Jose, CA, USA). Stained cells were analyzed by 
flow cytometry on a FACSCanto II cytometer (Becton Dickinson, 
San Jose, CA, USA), using FACS DIVA™ software V 6.0, and data 
analysis was conducted using FCS express (De Novo Software).
Staining of single-cell suspension of isolated brain immune 
cells was performed using standard protocols. Briefly, cells were 
stained for surface markers for 30 min at 4°C and washed twice 
before analysis. All staining procedures were completed at 4°C in 
DPBS containing 5 mM EDTA and 1% FCS. For all assays, the 
frequency of resident myeloid cells (RMC) or microglial cell was 
determined by flow cytometry gating on CD45lowCD11b+ cells 
since, the frequency of infiltrating myeloid cells (IMC) is corre-
sponding to CD45highCD11b+ cells. Furthermore, the frequency 
of monocytes is corresponding to CD45highCD11b+LY6C+ cells.
Fluorescence confocal Microscopy
For tissue fluorescence confocal microscopy, at different time 
points after surgery, mice were anesthetized, perfused with PBS, 
and then with 4% paraformaldehyde, sacrificed and the whole 
brains were obtained. After treatment with sucrose, brain tissues 
were cut on a freezing sliding microtome at a thickness of 10 μm 
(Shandom Cryotomo E, Thermo Fisher Scientific). The sections 
were mounted in adhesive slides (KNITTEL StarFrost® slides, 
Germany) and were then incubated with 5% normal goat serum 
(Sigma) in PBS, 0.05% Tween-20 (PBS-T-NGS), for 1 h to reduce 
nonspecific binding of antibodies to the cell surface and for cell 
permeabilization. An anti-LC3B (Cell Signaling Technology 
Beverly, MA, USA) plus anti-LAMP-1 (Abcam, Cambridge, UK) 
or plus anti-CD45 (Biolegend, San Diego, CA, USA) antibodies 
were applied to the slides, which were further incubated for 1 h 
at room temperature. After three rinses with PBS, the slides were 
incubated with Alexa Fluor 488 plus Alexa Fluor 546 secondary 
antibodies (Life Technology, Carlsbad, CA, USA) for 60 min. The 
slides were analyzed under a laser scanning confocal fluorescence 
microscope (Olympus FV300, Tokyo, Japan). In this experimen-
tal procedure, the injection sites were defined as the last section 
containing a visible needle track and the next section without the 
needle artifact. Quantification of LC3B+ microglial cell numbers 
and number of vesicles LC3B/LAMP-1+ cells in brain slides was 
performed using the software ImageJ (NIH, USA).
Detection of neuronal Degeneration
Neuronal degeneration was analyzed by the Fluoro-Jade B (FJB) 
techniques. In a first step, slides were staining with anti-NeuN 
antibody following staining procedures previously described. 
Briefly, slides were first immersed in a solution of 0.06% potas-
sium permanganate for 10 min. The slides were then rinsed in 
distilled water for 2  min. The staining solution was prepared 
from a 0.01% stock solution of FJB (Chemicon) according to the 
manufacturer’s instructions. To make up staining solution, stock 
solution was added to 0.1% acetic acid vehicle. This resulted in 
a final dye concentration of 0.0004% prepared within 10 min of 
use and was not reused. After 20 min in the staining solution, 
the slides were rinsed for 1 min in each of three distilled water 
washes. The slides were then placed on a slide warmer, set at 
approximately 50°C, until they were fully dry. The dry slides were 
cleared by immersion in xylene for at least 1 min before coverslip-
ping with DPX (Fluka, Milwaukee, WI, USA; or Sigma Chem. 
Co., St. Louis, MO, USA). The tissue was then examined using 
a laser scanning confocal fluorescence microscope (Olympus 
FV1000, Tokyo, Japan).
real-Time Pcr
Gene expression for iNOS, IL-1β, IL-6, TNFα, CCR2, and CCL2 
were assessed using semiquantitative real-time PCR. Briefly, RNA 
was isolated from CPU brain cells using a single-step phenol/chlo-
roform extraction procedure (Trizol; Life Technologies, Carlsbad, 
CA, USA) and depleted of contaminating DNA with RNase-free 
DNase kit (Life Technologies) before reverse transcription. 
Reverse transcription was performed on 1  µg of RNA using 
random hexamers as primers by the high-capacity cDNA RT kit 
(Life Technologies). Real-time PCR was performed by using One 
step plus Real-Time PCR System (Applied Biosystems, Foster 
City, CA, USA). Briefly, 5 ng of reverse-transcribed cDNA was 
used in triplicate samples. The assays were initiated with 2 min at 
50°C, 10 min at 95°C and then 40 cycles of 15 s at 95°C and 1 min 
at 60°C. Primers were obtained from Applied Biosystems (Foster 
City, CA, USA). Detection of all target genes and control HPRT 
was performed using SYBR® Green expression assays Master Mix 
(Applied Biosystems) and relative quantification (RQ) was calcu-
lated by using StepOne™ software V2.2.2 and the RQ = 2−ΔΔCt 
method, where Ct is the threshold cycle to detect fluorescence. Ct 
data were normalized to the internal standard HPRT. The primers 
sequences used are listed in Table 1.
statistical analysis
All experiments were performed at least three times and the 
results presented are from representative experiments. Statistical 
analyses were performed using either Student’s t-test for two-
group comparison, one-way ANOVA followed by Bonferroni 
post hoc test for more than two groups a one factor or two-way 
ANOVA followed by Bonferroni post hoc test for more than two 
factors. In all the experiments, p <  0.05 was considered to be 
statistically significant.
TaBle 1 | Real-time PCR primers.
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resUlTs
Pgn injection induces an increase in the 
Frequency of Mc in Mouse Brain 
Parenchyma
We have previously shown that PGN from S. aureus is a potent 
activator of BV2 microglial line cell (20). To examine in vivo if 
PGN is able to promote activation of resident microglial cells 
in mouse brain (35), we stereotaxically injected PGN into brain 
parenchyma (CPU). Microglial cells were analyzed in nervous tis-
sue slices by confocal immunofluorescence microscopy. Staining 
brain sections with CD45 allowed us to distinguish MC (CD45+) 
from astrocytes, oligodendrocytes, neurons (CD45−), and also 
CD45bright hematogenous population from CD45dim resident 
microglia. In brains from PBS-injected mice, microglia showed 
resting morphological features (36, 37), such as radial, non-
overlapping processes, a small cell soma and each cell appearing 
to occupy its own domain (Figure 1A). By contrast, after PGN 
injection, we observed rounded cells with enlargement of the 
soma, retraction and shortening of cell processes, resembling 
amoeboid microglia (Figure 1A). These morphological features 
are suggesting that PGN induce microglial activation (38), which 
agrees with our previous in vitro data.
Central nervous system damage commonly entails recruitment 
of circulating immune cells, resulting in an innate immune response 
that consists of resident microglia and peripherally derived mono-
cytes, macrophages, and dendritic cells (8, 39, 40). Thus, we wanted 
to determine whether PGN increased MC numbers into the brain 
parenchyma. After PGN injection, CPU was separated at different 
time points (24 h, 48 h, 72 h, 7 days, and 14 days) and analyzed 
for the presence of MC by flow cytometry. As expected, PGN 
resulted in a significant increase in the number of MC in all time 
points assessed; reaching a peak of cells recruited 72 h after injec-
tion (Figure 1B). These results correlated with the observation by 
confocal microscopy that the number of CD45+ cells, in the vicinity 
(next three sections without the needle artifact) of the site of injec-
tion, increased after the administration of PGN (Figure 1C). Then, 
to know whether PGN-induced leukocyte recruitment mostly 
confined to the vicinity of injection, we examined the injection 
site (ipsilateral-CPU), the opposite non-injected CPU control 
(contralateral-CPU), and the whole brain (Brain). We identified 
tissue RMC versus IMC by flow cytometry, using anti-CD45 plus 
anti-CD11b antibodies (20). PGN injection strongly enhanced the 
recruitment of inflammatory cells in the CPU, compared with con-
trols (Figures 1D,E). In contralateral-CPU and the whole brain, 
PGN also increased the number of MC, but in a weaker manner 
(Figures  1D,E). The increase in the number of MC was mainly 
due to a rise in the number of CD11b+CD45high fraction (IMC) in 
brains of PGN-injected mice (Figures 1D,F). In addition, we also 
observed an increase of RMC only confined to ipsilateral-CPU 
(Figures 1D,G). In agreement with the changes described in the 
literature for acute injured CNS (1, 41), in these experiments we 
found that PGN-induced microgliosis, microglial cell activation, 
and recruitment of IMC in brain tissue.
autophagy requirement for the 
recruitment of Mc to Brain Parenchyma 
after Pgn injection
We previously demonstrated that intracerebral injection of 
PGN increased autophagy of microglial cells (20). Atg8/LC3 is 
the most widely monitored autophagy-related protein, and it 
was originally identified as a subunit of microtubule-associated 
protein 1 light chain 3 (42). The induction of autophagy in 
PGN-injected mice was monitored by morphometric analysis 
after the formation of LC3B-labeled autophagosomes (≥1 μm) 
(43, 44). In this study, we confirmed that PGN induced an 
increase in the number of LC3B+ puncta in CD45+ cells, in the 
brain parenchyma, compared with control (Figures  2A,B). In 
addition, PI3K inhibitors, such as LY294002 and 3-MA, that 
block class I as well as class III PI3Ks, prevent autophagosome 
formation, and finally suppress autophagy (23, 45), were able 
to prevent the increase of LC3B punctate parenchymal MC by 
PGN treatment (Figures 2C–F,I). Moreover, we next examined 
whether PGN induces convergence of the autophagic pathway 
with a functional degradative compartment. Staining brain sec-
tions with antibodies against LC3B plus the LAMP1 allowed us to 
visualize the fusion of autophagosomes with lysosomes by confo-
cal microscopy (46, 47). Similarly, to our previous report (20), 
PGN injection into the CPU significantly induced overlapping 
signals of LC3B and LAMP1 compared with control, suggesting 
the autophagic flux is taking place (Figures 2G,H,J).
Next, we determined whether the presence of 3-MA and 
LY294002 affected inflammatory recruitment in the CPU of PGN-
injected mice. Wild-type (WT) mice were injected with PGN plus 
3-MA or PGN plus LY294002, 72 h later, the number of MC was 
analyzed by flow cytometry. Interestingly, we found that both 
autophagy inhibitors, 3-MA or LY294002, decreased the number 
of MC in the CPU of PGN-injected mice (Figure 3A), and this 
effect was mostly confined to MC in the ipsilateral side, since the 
analysis of the whole brain, showed that both inhibitors failed to 
modify the number of cell populations (Figure 3B). In addition, 
here we reveal that these autophagy inhibitors decreased the 
number of IMC cells in the PGN-injected parenchymal mice but 
increased the number of RMC (Figures 3C,D). Similar effects of 
FigUre 1 | PGN injection induces myeloid cells (MC) recruitment and microglia activation in brain. PGN or PBS was stereotaxically injected into the mouse caudate 
putamen (CPU). (a) At 72 h after injection, 10 µm brain sections were stained with an anti-CD45 (green) antibody. The slides were analyzed under a laser scanning 
confocal fluorescence microscope. In the PBS-quadrant, arrowheads indicate ramified resting parenchymal microglia, since in the PGN-quadrant, arrowheads 
indicate activated parenchymal microglial cells. (B) At indicated time points after injection, coronal brain slices of 2.0 mm containing the CPU from the injected 
hemisphere [caudate putamen (CPU)] were dissected. The tissue was homogenized, and CPU cells were costained with anti-CD45 (APC-Cγ7) and anti-CD11b 
(PERCPE) antibodies and analyzed by flow cytometry gating on CD11b+ CD45+ MC. The bar graph represents mean ± SD of number of MC from three separated 
experiments. (c) At 72 h after injections, coronal brain slices containing the CPU were photographed. Circle indicate injured injection site. These brain sections were 
stained with anti-CD45 (green) and then were analyzed under a laser scanning confocal fluorescence microscope, injection site is showed in the picture. (D) At 72 h 
after injection, CPU from injected hemisphere (Ipsilateral-CPU), or CPU of non-injected hemisphere (Contralateral-CPU), or the whole brain (BRAIN) were processed 
such as indicated in point B. Then, this brain cells were analyzed by flow cytometry gating on CD11b+CD45high infiltrating myeloid cells (IMC) and gating on 
CD11b+CD45low resident myeloid cells (RMC). (e–g) The bar graph represents mean ± SD of number of MC, of IMC, and of RMC from three separated 
experiments, respectively. * and *** indicate statistically significant (p < 0.05 and p < 0.001, respectively) changes compared with PBS-injected mice.
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these inhibitors were observed at the whole brain (Figures 3C,D). 
Taking into consideration that LY294002 and 3-MA inhibited 
the response to PGN and these molecules can inhibit autophagy, 
these results suggest that PI3K and autophagy response may be 
required for the MC recruitment in PGN-injected brains.
Tlr2 and MyD88 signaling regulates 
Pgn-induced leukocyte entry to the cns 
Parenchyma
To confirm the involvement of TLR2 and MyD88 adaptor protein in 
the recruitment effects of PGN, we studied leukocyte recruitment 
to mouse brain parenchyma after PGN intracerebral injection in 
TLR2KO and MyD88KO mice. We found that recruitment of 
MC in parenchymal CNS was significantly lower in TLR2KO 
mice compared with the WT mice, 72  h after PGN injection 
(Figures  4A,B). Consistent with this result, we observed that 
PGN injection in TLR2KO mice failed to increase the number of 
IMC, RMC in the ipsilateral-CPU and in whole brain, compared 
with the PGN-injected WT mice (Figures 4A,B). Similar results 
were obtained in MyD88KO mice, since we did not observe the 
major MC recruitment in the ipsilateral-CPU and whole brain 
of MyD88KO mice after PGN injection (Figures 4A,B). Taken 
together, our experiments demonstrate that the activation of 
FigUre 2 | PGN induces myeloid cell autophagy in brain inflammation model. PBS, 3MA, or LY2942002 was stereotaxically injected alone or in combination with 
PGN into the caudate putamen. (a–F) After 24 h, 10 µm brain sections were stained with anti-LC3B (red) plus anti-CD45 (green) or anti-LAMP-1 (green) antibodies. 
The slides were analyzed under a laser scanning confocal fluorescence microscope. (a–F) Arrows indicate the presence of LC3B positive punctuated cells. (g,h) 
Arrowheads indicate colocalization of LC3B positive vesicles with LAMP-1. (i) The bars graph represents mean ± SD of number of LC3B+ vesicles per CD45+ cell of 
three separated experiments. (J) The number of LC3B/Lamp-1 double-positive cells was obtained from 10 fields per slide, analyzing the next three sections without 
the needle artifact of three separated experiments. *** indicate statistically significant (p < 0.001) changes compared with un-stimulated cells.
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TLR2 by PGN and signaling through the MyD88 adaptor protein 
are an important regulator of leukocyte recruitment after PGN 
injection in the brain parenchyma.
As showed above, PI3K inhibitors regulate MC entry to 
PGN-injected CPU. As expected, in additional experiments, 
we observed that coinjection of PGN plus 3-MA or PGN plus 
LY294002 in TLR2KO and MyD88KO mice, did not reveal 
significantly differences in the leukocyte recruitment in the 
ipsilateral-CPU and whole brain of these mice compared with the 
controls (Figure 4C). Thus, this experiment suggests that PI3K 
inhibitors does not affect leukocyte entry to CNS parenchyma, in 
the absence of TLR2/MyD88-mediated PGN signaling.
Pi3K inhibitors Modulate inflammatory 
cell Phenotype and Pro-inflammatory 
Mediators in Pgn-injected cPU
Expression of MHC class II and CD80 and CD86 costimula-
tory molecules is associated with the ability to present antigen, 
and their detection can be used to indicate MC activation (48). 
Previous studies demonstrated that LPS (TLR4 ligand) was 
able to increase MHC class II, CD80, and CD86 expression in 
primary microglia isolated from human adult patients (49). 
However, there is little evidence in the literature if another TLR 
family members, such as TLR2, could regulate activation of 
microglia, within damaged CNS. Here, we explored the expres-
sion of molecular markers related to the cell activation, in MC 
from PGN-injected mice, in the presence/absence of autophagy 
inhibitors. We found that PGN injection increased expression 
of MHC class II and CD86 in microglial cells and monocytes. 
Interestingly, 3-MA and LY294002 treatment prevented the 
effects of PGN on the expression of both molecular markers in 
these cell types (Figures  5A,B). Chemokines and their recep-
tors are expressed in the CNS, where they play key functions in 
development and maintenance (50, 51). For instance, CX3CL1/
CX3CR1 signaling modulates stimulus-dependent microglial 
activation (52). Moreover, CXCR4 is upregulated in microglia 
and astrocytes in various brain diseases, such as HIV encephalitis 
FigUre 3 | PGN-induced myeloid cell recruitment requires PI3K. PGN or PBS was injected with 3-methyladenine (3-MA) or LY2942002 into the caudate putamen 
(CPU). (a) At 72 h after injection, CPU or BRAIN cells were analyzed by flow cytometry gating on MC. (B–D) The bar graph represents mean ± SD of number of 
MC, of infiltrating myeloid cells and of resident myeloid cells from three separated experiments. * and *** indicate statistically significant (p < 0.05 and p < 0.001, 
respectively) changes PGN + 3-MA or PGN + LY2942002 compared with PGN-injected mice.
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and experimental allergic encephalomyelitis (53, 54). We inves-
tigated the expression of CXCR4 and CX3CR1 in microglia and 
infiltrating monocytes after PGN intracerebral injection. We 
observed that PGN increased CXCR4 and CX3CR1 expression 
in microglia compared to the control, and their expression was 
significantly inhibited in the presence of LY294002 (Figure 5C). 
However, this inhibitor did not affect the chemokines expression 
in monocytes from PGN-injected mice (data not shown). In 
addition, we investigated whether CCL2 and CCR2 are increased 
in PGN-injected mice compared with controls. This signaling 
axis is important on monocyte recruitment to CNS tissue during 
immune-mediated inflammation (55). We detected increased 
CCL2/CCR2 gene expression in PGN-injected CPU, compared 
with controls (Figure  5D), which was prevented by LY294002 
injection (Figure  5D). Microglia activation is associated with 
the secretion of cytokines that later can modulate their activa-
tion state. High levels of pro-inflammatory cytokines such as 
TNF-α, IL-6, and IL-1β were found elevated in the brain tissue 
from patients with neurological diseases (56). It has also been 
reported that PGN increases iNOS and COX-2 expression in BV2 
microglial cells by binding to the TLR2 receptor/MyD88 which 
in turn activates PI3K/AKT/NF-kappa B signaling pathway 
(57). Here, we observed that PGN injection promoted iNOS, 
IL-1β, IL-6, and TNF-α gene expression compared with controls 
(Figure 5E). In addition, we studied if PI3K inhibition modulates 
pro-inflammatory cytokines expression after PGN treatment. We 
found that coinjection LY294002 with PGN into CPU, prevented 
PGN-induced iNOS and IL-1β production (Figure  5E), but 
PGN-induced IL-6 production was increased in presence of 
this inhibitor (Figure  5E). Moreover, LY294002 was not able 
to change PGN-induced TNF-α production (Figure 5E). These 
results suggest that PI3K inhibitors could selectively regulate 
iNOS and IL-1β production, in addition to leukocyte recruit-
ment, in PGN-injected mice.
FigUre 4 | PGN-induced myeloid cell recruitment requires MyD88/TLR2 signaling. (a) PGN or PBS was injected into the caudate putamen (CPU) from MyD88 KO, 
TLR2KO, or C57BL/6 mice. At 72 h after injection, CPU or BRAIN cells were analyzed by flow cytometry gating on MC. (B) The bar graph represents mean ± SD of 
number of MC, of infiltrating myeloid cells (IMC) and of resident myeloid cells (RMC) from three separated experiments. * and *** indicate statistically significant 
(p < 0.05 and p < 0.001, respectively) changes PGN-injected TLR2 KO mice or PGN-injected MyD88 KO mice compared with PGN-injected wild-type (WT) mice. 
(c) The bar graph represents mean ± SD of number of MC, of IMC, and of RMC from three separated experiments. * and *** indicate statistically significant 
(p < 0.05 and p < 0.001, respectively) changes PGN + 3-methyladenine (3-MA) or PGN + LY2942002 injected WT mice compared with PGN-injected WT mice.
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Pi3K inhibitors Prevent Pgn-induced 
neuronal cell Death
Finally, we examined if PGN was able to induce neuronal dam-
age in mouse brain, using FJB staining and confocal microscopy. 
We detected neuronal toxicity generation in CPU sections of 
PGN-injected mice compared with the controls (Figures 6A,C). 
Furthermore, we observed that the coinjection of LY294002 
reduced neuronal cell death induced by PGN (Figures 6B–D). 
Therefore, these data suggest that PI3K signaling regulate neu-
ronal damage induced by PGN injection.
DiscUssiOn
Recent studies have provided key insights into TLR-mediated 
activation of PI3K, suggesting that the outcome of PI3K activa-
tion downstream of these immune receptors depends on both the 
TLR that is stimulated and the cell type being activated (34). In 
this study, we have uncovered a completely novel role for PI3K in 
the control of brain inflammation. We have shown that the PGN 
injection into the brain parenchyma triggered LC3B+ puncta in 
CD45+ cells, LC3B and LAMP1 colocalization, recruitment of 
MC to the injection site, pro-inflammatory mediators’ produc-
tion, and neurodegeneration. Moreover, these effects of PGN 
were prevented by PI3K inhibitors (including 3-MA). To the best 
of our knowledge, this is the first demonstration that class III and 
class I PI3K inhibitors, that may also modulate autophagy, a fun-
damental homeostatic cell process, could control inflammatory 
response in the CNS after TLR2 stimulation.
Myeloid cells in CNS represent a heterogeneous class of 
innate immune cells that contribute to the maintenance of tissue 
homeostasis differentially during development and adulthood 
(58, 59). Microglia are the only MC type in the CNS parenchyma 
under the steady-state conditions and act as the first line of 
FigUre 5 | Inhibition of PI3K modulates PGN-induced pro-inflammatory myeloid cells activation. PGN or PBS was injected with 3-methyladenine (3-MA) or 
LY2942002 into the caudate putamen (CPU). (a–c) At 72 h after injection, CPU cells were stained with anti-IA/IE, anti-CD86, anti CXCR4, and anti-CX3CR1 
antibodies and analyzed by flow cytometry gating on microglial cells (CD11b+CD45low cells) or monocytes (CD11b+CD45highLy6C+). The bar graph represents 
mean ± SD of mean fluorescence intensity (MFI) from three separated experiments. * and *** indicate statistically significant (p < 0.05 and p < 0.001, respectively) 
changes PGN compared with PBS-injected mice, # indicate statistically significant (p < 0.05 and p < 0.001, respectively) changes PGN + 3MA or 
PGN + LY2942002 compared with PGN-injected mice. (D,e) At 72 h after intracerebral injection, total RNA was extracted from CPU tissues and examined for 
mCCR2, mCCL2 miNOS, mIL-1β, mIL-6, and mTNF-α genes expression by real-time PCR. Arbitrary units were used to indicate the fold difference in PGN versus 
PBS-injected mice after normalization with the HPRT transcripts. # indicate the fold difference in PGN + LY2942002 versus PGN-injected mice.
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defense in the nervous system (8). The morphologically “resting” 
microglia are continually surveying their microenvironment with 
their highly motile processes. Upon detection of focal injury to 
the brain, microglial processes rapidly move toward the lesion 
site, and switching their behavior, leading to focal microglial 
activation (35). This work provides evidence that PGN-induced 
focal activation of microglia confined to the CPU. We observed 
microglial cell accumulation with morphology distinguishable 
from the resident microglial cells, consisting of shorter, asym-
metrically oriented processes as well as enlarged cell bodies 
nearly to the injection site. In addition, we demonstrated that 
PGN present in the mouse brains not only induced microgliosis 
but also augmented other CNS-infiltrating MC populations in the 
injected site. In line with these findings, other authors previously 
reported that PGN in the brain of multiple sclerosis patients 
could contribute to the disease progression through the activa-
tion of infiltrating dendritic cells (60). Recently, Luz et al. found 
that TLR2 activated in CNS affects the innate but not adaptive 
brain immune responses. Our findings revealed that stimulation 
of TLR2 in brain parenchyma (CPU) triggers MC recruitment in 
the several areas analyzed (61). We observed that PGN increased 
MC numbers in CNS 72 h after injection, but this response was 
controlled 14 days after treatment. This evidence suggests that the 
parenchymal PGN injection could temporally activate CNS MC, 
which mediate local inflammation and later these cell popula-
tions return to steady state.
FigUre 6 | Pharmacological inhibition of PI3K prevents neuronal loss in PGN-injected brain. PGN or PBS was injected with LY2942002 into the caudate putamen. 
(a–D) At 72 h after injection, 20 µm brain sections were stained with anti-NeuN (red) antibody. Then, the slides were stained with Fluor-Jade B (FJB) work solution 
and analyzed under a laser scanning confocal fluorescence microscope. Arrowheads indicate the presence of FJB positive neuron cells. The bars graph represents 
mean ± SD of number of FJB + neuron cells from three separated experiments. *** indicate statistically significant (p < 0.001) changes PGN compared with 
PBS-injected mice.
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Under normal conditions, microglial cells contribute to 
the restriction of other MC to access the CNS parenchyma. 
However, neuroinflammatory circumstances, such as neural 
injury or local inflammation, trigger defined molecular 
mechanisms that allow other non-parenchymal mononuclear 
phagocytes (those found in the choroid plexus, meninges, and 
perivascular spaces) and peripheral immune cells to breach 
the glia limitans and enter the CNS parenchyma (62, 63). We 
observed that PGN injection into brain parenchyma lead to 
the migration of MC, which were mostly confined around the 
injection site. Interestingly, two PI3K inhibitors, such as 3-MA 
and LY294002, were able to block this MC recruitment. Taking 
into consideration that 3-MA prevent autophagosome forma-
tion, these results indicate that microgliosis and recruitment of 
others MC induced by TLR2 activation may require autophagy 
activation. These results are in agreement with a recent publi-
cation showing that genetic inhibition of autophagy prevented 
irradiation-induced microglial activation and neuroinflamma-
tion (64). On the other hand, Jin et al. found that intracerebral 
administration of the autophagy inhibitor 3-MA promoted 
microglia activation after traumatic brain injury (65). Taking 
into consideration the results of the present study and other 
reports, we propose that autophagy may play different roles in 
modulation of MC activation and inflammation, depending on 
the inflammatory context and other microenvironment factors. 
For instance, basal levels of autophagy are required for normal 
neuron survival (28, 66), while overactivated autophagy induces 
autophagic cell death (67).
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Although no solid evidence about the role of MC autophagy 
on brain inflammation has emerged, recent research showed 
that neuronal TLR2 activation has been associated with the 
increased levels of the autophagy/lysosomal pathway marker 
p62 as well as with the recruitment and activation of microglia 
in the substantia nigra of PD brain (68). In this sense, autophagy 
is regulated by a plethora of immunological signals, including 
ligands for pattern-recognition receptors, for example, TLRs 
and cytokines (69, 70). In this article, we showed that PGN, a 
TLR2 ligand, triggers autophagy activation in brain MC and 
autophagolysosome formation, and this effect was blocked by 
PI3K inhibitors. Considering all these results, we explored the 
role of TLR2 signaling in PGN-induced brain inflammation. We 
observed that TLR2 and the common TLR signaling adaptor 
MyD88 were required for the PGN-induced MC recruitment 
and MyD88 and TLR2 deficiency mainly affected infiltrating 
MC accumulation instead resident MC. In accordance with 
our results, it was described in the literature that MyD88/TLR2 
signaling regulated infiltration of the peripheral immune cells 
populations and microglial expansion in response to the acute 
brain inflammation (71, 72). Thus, we confirm that MyD88/
TLR2 signaling plays a pivotal role in PGN-induced inflamma-
tory response and this effect may involve PI3K and autophagy 
activation in CNS MC.
Several pro-inflammatory factors produced by CNS MC 
also influence the evolution of neuroinflammatory injury (73). 
Previous studies have shown that inflammation leads to the 
accumulation of perivascular macrophages and microglial cells at 
the inflammatory site, and they upregulate MHC class II expres-
sion and costimulatory molecules (74). In agreement with these 
studies, we also revealed that PGN injection increased MHC-II 
and CD86 expression in microglia and monocytes at the inflam-
matory site and PI3K inhibition reduced these PGN effects. These 
findings are in agreement with the concept that MC in the CNS 
are highly specialized but also plastic cells, that become reactive 
in the context of any changes in CNS homeostasis. In this sense, 
we suggest that the PI3K pathway participate in determining the 
phenotypic profile of MC and its inhibition could lead to limita-
tion of CNS inflammation.
Multiple mechanisms could account for the induction in MC 
recruitment observed in PGN-injected mice. Based on previous 
reports describing that fractalkine/CX3CR1 signaling regulates 
microglial behavior in several CNS disorders (75), we evaluated 
the CX3CR1 expression in microglial cells after PGN treatment. 
Interestingly, since we observed that PGN increased CX3CR1 
expression in these cells, LY294200 was able to attenuate this 
PGN-effect. In addition, we found that PGN also increased 
CXCR4 expression in microglial cells, and this upregulation was 
diminished by PI3K inhibition. These findings suggest that inhibi-
tion of PI3K could regulate inflammatory response in CNS from 
PGN-injected mice involving mechanisms that reduce migration 
of peripheral MC to injury site and modulate phenotype profile 
of resident MC.
In pathological conditions, microglia can activate endothelial 
cells by the release of reactive oxygen species and cytokines such 
as IL-1α, IL-1β, IL-6, and TNF-α (76, 77). Also, the recruitment 
of peripheral immune cells can be initiated by microglia through 
the secretion of the chemokine CCL2 under inflammatory 
conditions (78). Here, we demonstrated that PGN promoted and 
increase in iNOS, IL-1β, IL-6, and TNF-α gene expression in cells 
from the injection site. Moreover, PI3K inhibition differentially 
modulated gene expression of these mediators. Finally, in this set 
of experiments, we observed an increase in CCR2 and CCL2 gene 
expression in CPU from the PGN-injected mice compared with 
the control animals. Interestingly, LY294200 diminished gene 
expression of both molecules studied.
There are different glial cell populations (astrocytes and 
microglial cells) and infiltrating MC, responsible for the release 
of inflammatory mediators in the CPU from PGN-injected mice. 
Therefore, we suggest that the global effect of PI3K inhibition of 
inflammatory mediator expression may be affected by the pres-
ence of different cell types, that may produce distinct mediators, 
since PI3K signaling modify cell recruitment.
Brain inflammation is a typical feature of neurodegenerative 
diseases (79–81) and could be prominent sequel of many acute 
forms of brain injury (for example, trauma, encephalitis, and 
stroke) (82, 83). Under certain circumstances, neuroinflamma-
tion is known to promote neuronal death (84). Our findings sug-
gest that PGN induced neuronal cell death involving autophagy 
activation. Indeed, our studies have shown that MC exposed to 
PGN failed to be toxic to neighboring neurons in the presence of 
LY294200.
In this sense, was reported that autophagy activation in 
cerebral ischemia has a destructive role but this effect was 
prevented by the administration of 3-MA (85, 86). Conversely, 
other evidences have suggested that autophagy has a neuro-
protective function (87, 88). We support the idea that physi-
ological levels of autophagy are favorable to neuronal survival, 
but excessive or inadequate levels, could be harmful and cause 
injury.
To summarize, this study suggests a new role for PI3Ks and 
PGN-induced autophagy, in MC recruitment to the CNS and 
brain inflammation. Considering that recent discoveries point 
to autophagy as a substantial regulator of CNS innate immune 
responses and our findings that pharmacological inhibitors of 
class I and class III PI3K can suppress both, the inflammatory 
response and neuronal toxicity, we proposed that these molecules 
could potentially be consider as targets for exploration and 
development of new therapeutic strategies for neurodegenerative 
diseases.
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